Immunization with LRV1c+CpG was specific to the <i>Leishmania</i> RNA virus capsid.

<p>C57BL/6 mice were immunized 3 times IM, 15 days apart with LRV1c+CpG or PBS as a control. 21 days after the third vaccination, mice were infected with either LRV1+ <i>Lg</i> or LRV1- <i>Lg</i>. (A) Change in footpad swelling of mice immunized with LRV1c+CpG (white square) or vehicle control (black square) and infected with LRV1+ <i>Lg</i>. (B-C) <i>In vivo</i> bioluminescence of mice challenged with LRV1c+CpG (white) or vehicle control (black) and infected with LRV1+ <i>Lg</i> at the peak of infection. (D) Change in footpad swelling of mice immunized with LRV1c+CpG (white circle) or vehicle control (black circle) and infected with LRV1- <i>Lg</i>. (E-F) <i>In vivo</i> bioluminescence of mice immunised with LRV1c+CpG (white) or vehicle control (black) and infected with LRV1- <i>Lg</i> at the peak of infection. Results are means±SEM. (A and D) Statistical significance tested by a two-way ANOVA, using Prism5 Graphpad software (n = 5, *: P<0.05, **: P<.005, ***: P<0.0005). (B-E) Statistical significance tested by a 2-tailed Student’s t-test using Prism5 Graphpad software (n = 5, *: P<0.05, **: P<0.005, ***: P<0.0005). Representative of 8 independent experiments.